1620O Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma.
Saved in:
| Title: | 1620O Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma. |
|---|---|
| Authors: | Ludwig, J.A.1 (AUTHOR), Federman, N.2 (AUTHOR), Anderson, P.3 (AUTHOR), Macy, M.E.4 (AUTHOR), Davis, L.E.5 (AUTHOR), Riedel, R.F.6 (AUTHOR), Muscal, J.A.7 (AUTHOR), Daw, N.C.8 (AUTHOR), Ratan, R.1 (AUTHOR), Toretsky, J.9 (AUTHOR), Ianopulos, X.10 (AUTHOR), Hsu, F.J.11 (AUTHOR), Breitmeyer, J.B.11 (AUTHOR), Meyers, P.12 (AUTHOR) |
| Source: | Annals of Oncology. 2020 Supplement 4, Vol. 31, pS972-S972. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2020.08.1846 |
